From: Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
Lung volume measurement | Before nintedanib | On nintedanib | P value |
---|---|---|---|
Duration of CT follow-up (days) | 361 ± 429 (range: 92–1277) | 452 ± 357 (range: 120–1247) | 0.575 |
Δ LUL volume (mL/year) | − 125 ± 211 | − 90 ± 125 | 0.575 |
Δ LLL volume (mL/year) | − 83 ± 218 | − 42 ± 123 | 0.575 |
Δ RUL volume (mL/year) | − 107 ± 210 | − 58 ± 56 | 0.484 |
Δ RML volume (mL/year) | − 36 ± 92 | − 12 ± 51 | 0.889 |
Δ RLL volume (mL/year) | + 155 ± 662 | − 86 ± 98 | 0.575 |
Δ carinal surface/year | + 9.07 ± 139 | + 52 ± 70 | 0.401 |
Δ APDT (mL/year) | − 14.8 ± 21 | − 6.5 ± 20 | 0.401 |
ΔTDT (mL/year) | − 306 ± 1113 | − 2.86 ± 9.23 | 0.889 |